Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 9/20 | 0.36 |
| ▸ | CNR1 | P21554 | 8/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3299672 | 0.87 | MAPT (0.39) | MAPTL3MBTL1ATMHPGDCYP1A2 | |
| SCHEMBL3296512 | 0.85 | L3MBTL1 (0.43) | MAPTL3MBTL1HPGDTLR8TSHR | |
| SCHEMBL3297896 | 0.85 | CYP1A2 (0.41) | MAPTL3MBTL1ATMCYP1A2CYP2C9 | |
| SCHEMBL3298706 | 0.82 | TSHR (0.41) | MAPTL3MBTL1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3297828 | 0.80 | TAAR1 (0.42) | MAPTL3MBTL1TSHR | |
| SCHEMBL3296233 | 0.79 | ESR1 (0.48) | MAPTL3MBTL1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3298810 | 0.78 | HTT (0.40) | L3MBTL1CYP1A2CYP2C9CYP2C19TLR8 | |
| SCHEMBL20663194 | 0.76 | L3MBTL1 (0.54) | MAPTL3MBTL1ATMHPGDCYP1A2 | |
| SCHEMBL3297582 | 0.75 | THRA (0.43) | CYP1A2CYP2C9CYP2C19TLR8NPSR1 | |
| SCHEMBL3299978 | 0.75 | GRIN2D (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7741393-B2 | Organic silicon-based compound and method of producing the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-22 | — | — | US | disclosed |
| US-20070203275-A1 | Organic Silicon-Based Compound And Method Of Producing The Same | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203275-A1 | Organic Silicon-Based Compound And Method Of Producing The Same | ARSA, OR10J3, HDAC10 | MAPT 2685/4885L3MBTL1 1173/4885ATM 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.